Aclaris Therapeutics announces $20.0 million private placement
Aclaris announced it has entered into a stock purchase agreement with a group of institutional accredited investors for the private placement of 1,081,082 shares of common stock at a purchase price of $18.50 per share, yielding expected gross proceeds of $20.0 million. May 27, 2016